Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679855 · ClinicalTrials.gov registry record · Phase 3
Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial
A Phase 3 study of Post-ligation Cardiac Syndrome, sponsored by NICHD Neonatal Research Network.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 316
- Enrollment target
- 19
- Study locations
NCT06679855 is a Phase 3 study of Post-ligation Cardiac Syndrome that is actively recruiting participants, run by NICHD Neonatal Research Network. The registered enrollment target is 316 participants. The trial reports 19 study locations across 15 states.
The verdict
NCT06679855, a Phase 3 study of Post-ligation Cardiac Syndrome, is actively recruiting participants, sponsored by NICHD Neonatal Research Network.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 316 participants
- Enrollment target
- 19
- Study locations
Study Summary
The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decreases the risk of death or PLCS within 7 days of the procedure, compared to standard treatment; and 2. to determine the effects of milrinone on two-year survival and neurodevelopmental outcome.
Conditions Studied
Interventions
- DRUG Placebo infusion
- DRUG Milrinone infusion
Study Locations (19)
California
- Children's Hospital of Orange County - Orange
- Stanford University - Palo Alto
- Sharp Mary Birch Hospital for Women & Newborns - San Diego
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Case Western Reserve University - Cleveland
Texas
- University of Texas Southwestern - Dallas
- University of Texas at Houston - Houston
Alabama
- University of Alabama - Birmingham - Birmingham
Georgia
- Emory University - Atlanta
Illinois
- Northwestern Lurie Children's Hospital of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 316 participants |
| Start Date | 2025-06-13 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679855
The ClinicalTrials.gov registry entry for NCT06679855 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 316 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-ligation Cardiac Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo infusion is the first listed.
NCT06679855 reports 19 study locations spanning 15 distinct geographic areas - top geographies include California, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT06679855 about?
NCT06679855 is a clinical study titled "Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial". The goal of this Phase 3, randomized, masked clinical trial is to is to find out whether milrinone, when given to infants after PDA closure, will help the heart work better by supplying oxygen to the lungs and tissues. The main questions it aims to answer are: 1. to determine if milrinone decrease...
What is the current status of trial NCT06679855?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 316 participants. The study started on 2025-06-13. Estimated completion is 2029-06-30.
What conditions does trial NCT06679855 study?
This clinical trial studies the following conditions: Post-ligation Cardiac Syndrome.
What interventions are being tested in trial NCT06679855?
The interventions under investigation include: Placebo infusion (DRUG), Milrinone infusion (DRUG).
Who is sponsoring clinical trial NCT06679855?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679855 being conducted?
This trial has 19 study locations across Alabama, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.